rethinkTHC Search
Menu
Study breakdown

Opioid users showed blunted endocannabinoid stress response compared to healthy controls

Case ControlPreliminary evidence
The takeaway

After social stress, healthy controls showed increased 2-AG endocannabinoid levels while chronic non-medical opioid users showed a blunted response, suggesting dysfunction in the endocannabinoid stress buffer system that may contribute to opioid use vulnerability.

Addiction researchers, clinicians treating opioid use disorder, and readers interested in endocannabinoid system function.

Opioid users showed blunted 2-AG stress response at all post-stress time points vs controls

What the researchers found

A significant GROUP x TIME interaction was found for 2-AG. Healthy controls showed increased 2-AG plasma levels after social exclusion stress, while non-medical opioid users showed a blunted stress response. The groups robustly differed at all time points after stress. Higher 2-AG levels were associated with greater feelings of social inclusion. No significant interactions were found for anandamide, other NAEs, or arachidonic acid.

Why it matters

The endocannabinoid system is increasingly recognized as a critical stress buffer. If opioid use disrupts this buffering capacity, specifically the 2-AG response, it could explain why stress is such a powerful trigger for opioid relapse and why opioid users are vulnerable to emotional dysregulation.

The numbers in context

21 NMPOU participants vs 29 healthy controls. Blood collected at 5 time points. Significant GROUP x TIME interaction for 2-AG (p significant). Robust group differences at all post-stress time points. Higher 2-AG associated with greater social inclusion feelings. No significant interactions for AEA, NAEs, or AA.

How the study worked

Individuals with chronic non-medical prescription opioid use (n=21) and matched opioid-naive controls (n=29) underwent social exclusion using the Cyberball task. Plasma was collected before and at 10, 20, 30, and 60 minutes after stress. 2-AG, anandamide, related N-acylethanolamines, and arachidonic acid were measured.

What this study cannot tell us

Small sample sizes (21 vs 29) limit generalizability and statistical power. Cross-sectional comparison cannot determine whether the blunted response preceded or resulted from opioid use. Social exclusion (Cyberball) may not represent the types of stress that trigger real-world relapse. Plasma endocannabinoids may not perfectly reflect brain levels.

How to read the evidence

Small case-control study with repeated measures and objective biomarkers, providing mechanistic insight but limited by sample size and cross-sectional design.

When this study was published

Published in 2026.

The bigger picture

This finding links the opioid and endocannabinoid systems in a clinically meaningful way. If 2-AG dysfunction contributes to stress vulnerability in opioid use disorder, pharmacological approaches that enhance 2-AG signaling (such as MAGL inhibitors) could represent a novel treatment strategy, potentially more targeted than broad cannabinoid receptor agonists.

Questions still open

  • Does the blunted 2-AG response recover after sustained opioid abstinence? Could cannabis or cannabinoid therapies restore the stress buffer in people with opioid use disorder? Is 2-AG dysfunction present in other substance use disorders?

Common questions

What is 2-AG?
2-arachidonoylglycerol is one of the two main endocannabinoids produced naturally by the body. It plays a key role in the brain's stress response system, helping to buffer emotional reactions to threatening or stressful situations.
Could cannabis help opioid users cope with stress?
This study suggests opioid users have a deficit in endocannabinoid stress buffering. While cannabis activates the same system, whether it would restore healthy stress responses or create additional problems is unclear and would need careful research.

Read the original research

Endocannabinoid response to social stress in chronic non-medical prescription opioid users.

Psychopharmacology, 243(2), 427-441

Citation

Schmid, Vinzenz K; Quednow, Boris B; Pellegata, Daniele; Meier, Philip; Gertsch, Jürg; Kroll, Sara L. (2026). Endocannabinoid response to social stress in chronic non-medical prescription opioid users.. Psychopharmacology, 243(2), 427-441. https://doi.org/10.1007/s00213-025-06950-4

Explore the wider topic